Inclisiran vs PCSK9 Inhibitors: Injection Frequency

If you need a powerful LDL-lowering injection and your biggest concern is how often you have to go in for a shot, inclisiran wins by a wide margin: two injections per year once you are past the initial loading phase, compared to every two weeks or every month for the PCSK9 monoclonal antibodies evolocumab and alirocumab. Both approaches cut LDL cholesterol by roughly 50 percent on top of maximally tolerated statin therapy. The difference is not efficacy — it is logistics.

This explainer draws on peer-reviewed research from three lipid specialists listed in the Convene directory. Anne Goldberg, MD, at Washington University School of Medicine co-authored the landmark 2013 ACC/AHA cholesterol treatment guideline [1] and the National Lipid Association guidance on familial hypercholesterolemia [2], the population most likely to need these drugs; she also led a randomized controlled trial evaluating bempedoic acid as a non-injection alternative for patients who cannot reach LDL goals [3]. Eliot Brinton, MD, at Intermountain Medical Center, co-authored the AACE/ACE comprehensive guidelines on dyslipidemia management [4] and a major American Heart Association statement on statin safety [5] — the statin safety work is directly relevant because statin-intolerant patients are often the first candidates for injectable PCSK9-targeting therapy. Robert Eckel, MD, at the University of Colorado, co-authored the 2013 ACC/AHA guideline alongside Goldberg [1] and published foundational work on metabolic syndrome [7], the cluster of conditions that often drives the LDL problems that eventually require these agents.

How both approaches work

Both inclisiran and the PCSK9 monoclonal antibodies target the same biological pathway — but from different directions.

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein the liver makes that destroys LDL receptors. Fewer LDL receptors on liver cells means less LDL gets cleared from the blood, so levels rise. Both classes of drug block this process, restoring receptor activity so the liver can pull more LDL out of circulation.

The PCSK9 monoclonal antibodies — evolocumab (Repatha) and alirocumab (Praluent) — work by intercepting the PCSK9 protein itself in the bloodstream. Each injection delivers antibodies that bind circulating PCSK9 before it can destroy LDL receptors. Because the antibodies eventually break down and the liver keeps producing PCSK9, you need a new dose every two weeks or every four weeks to keep levels suppressed.

Inclisiran takes a different route. It is a small interfering RNA (siRNA) — a tiny genetic messenger that travels to liver cells and switches off the gene instructions the liver uses to produce PCSK9 in the first place. Because it acts inside the cell rather than in the bloodstream, a single dose has a much longer silencing effect. The dosing schedule reflects this: one injection at the start, a second injection at three months, then one injection every six months after that.

At a glance

What the evidence shows on LDL reduction

The ORION phase 3 trials established inclisiran's efficacy profile. In ORION-10 and ORION-11, patients with established cardiovascular disease or at high risk who were already on maximally tolerated statin therapy saw sustained LDL reductions of 50 to 55 percent. The twice-yearly dosing produced consistent trough levels — meaning the drug kept working even at the end of the six-month dosing interval, not just right after the injection.

Evolocumab's FOURIER trial enrolled more than 27,000 patients with established atherosclerotic cardiovascular disease on statin therapy. LDL dropped by about 59 percent, and patients had a 15 percent reduction in the composite cardiovascular outcome (heart attack, stroke, cardiovascular death) compared with placebo. Alirocumab's ODYSSEY OUTCOMES trial enrolled over 18,000 patients after acute coronary syndrome and showed similar LDL reduction, with a significant reduction in major cardiovascular events.

Inclisiran does not yet have completed cardiovascular outcomes data — the ORION-4 trial is ongoing and expected to report in the mid-2020s. For a patient whose doctor wants established outcomes evidence before prescribing, the PCSK9 antibodies have that; inclisiran does not yet.

Who is most likely to need one of these drugs

The 2013 ACC/AHA cholesterol guideline co-authored by Anne Goldberg and Robert Eckel established a framework that most lipid specialists still follow: start with high-intensity statin therapy for patients at high cardiovascular risk, maximize the dose, and if LDL remains too high, add further therapy [1]. Injectable PCSK9-targeting agents sit at that next step.

The patients most often in this situation fall into two main groups. The first is people with familial hypercholesterolemia (FH) — an inherited condition where LDL is high from birth due to mutations in LDL receptor genes. The National Lipid Association expert panel guidance on FH, for which Anne Goldberg served as lead author, makes the case for aggressive LDL reduction (at least 50 percent) in these patients, who often cannot reach goal on statins alone [2]. PCSK9-targeting drugs were transformative for this population.

The second group is people with established cardiovascular disease — a prior heart attack, stroke, or documented coronary artery disease — who need LDL below 70 mg/dL (and often below 55 mg/dL per newer guidelines) but cannot get there on statin therapy alone. This includes patients who are statin-intolerant.

The AHA statin safety statement co-authored by Eliot Brinton documents that true statin-induced muscle injury severe enough to require stopping is rare — under 0.1 percent of patients — but subjective complaints lead roughly 10 percent of patients to discontinue therapy [5]. For someone who has genuinely tried maximally tolerated statins and cannot take a meaningful dose, an injectable PCSK9-targeting agent may be the primary LDL-lowering tool rather than an add-on.

The injection frequency question in practice

For most patients, going from 26 injections per year (biweekly PCSK9 antibody dosing) down to 2 injections per year is meaningful. Self-injection fatigue is real. Patients on multiple injectable medications — insulin, GLP-1 agonists, weekly methotrexate — often describe injection burden as one of the top reasons they skip doses or stop treatment.

There is a practical wrinkle with inclisiran: the twice-yearly injections are often administered in a clinical setting (a doctor's office or pharmacy) rather than self-injected at home, at least under the initial FDA approval. The PCSK9 antibodies are designed for home self-injection. If getting to a clinic every six months is harder than self-injecting every two weeks, the calculus flips. Your specific situation matters.

Measuring LDL accurately

One technical point worth knowing: how your LDL is measured affects treatment decisions. The Friedewald equation — the standard calculation used in most routine labs — estimates LDL from total cholesterol, HDL, and triglycerides. Research co-authored by Eliot Brinton found meaningful discrepancies between Friedewald-estimated and directly measured LDL, particularly at lower LDL levels [6]. This matters when your doctor is trying to decide whether you have reached a target of 70 mg/dL or 55 mg/dL. If you are near a treatment threshold, ask whether your lab uses a calculated or directly measured LDL result.

What about non-injection options

Inclisiran and the PCSK9 antibodies are not the only add-on options when statins are not enough. The 2017 AACE/ACE dyslipidemia guidelines co-authored by Eliot Brinton cover the full menu, including ezetimibe (a daily pill that blocks cholesterol absorption in the gut) as a well-tolerated first add-on [4].

For patients who want to avoid injections entirely, bempedoic acid is a more recent oral option. A randomized controlled trial in JAMA led by Anne Goldberg evaluated bempedoic acid in 779 patients with established cardiovascular disease or familial hypercholesterolemia who were already on maximally tolerated statins. The addition of bempedoic acid reduced LDL by an average of 17.4 percentage points more than placebo over 12 weeks — a meaningful reduction, though smaller than what the injectable agents produce [3]. Bempedoic acid does not cause the muscle-related side effects associated with statins because it is only activated in the liver, not in muscle tissue, making it relevant for statin-intolerant patients.

Questions to ask your doctor

• Have I truly reached my maximally tolerated statin dose, or is there room to optimize before adding an injectable?
• Do I have familial hypercholesterolemia, and if so, what LDL target does my risk level call for?
• Is the injection frequency difference between inclisiran and the PCSK9 antibodies likely to affect whether I stay on the medication?
• Does my situation call for a drug with proven cardiovascular outcomes data, or is LDL reduction alone sufficient evidence for now?
• Would starting with ezetimibe or bempedoic acid make sense before moving to an injectable?
• How is my LDL being measured — and should I have a direct measurement done?

The bottom line

Inclisiran and the PCSK9 monoclonal antibodies produce similar LDL reductions — both around 50 percent on top of statin therapy. The meaningful difference is how often you receive an injection: twice a year for inclisiran versus every two to four weeks for evolocumab or alirocumab. The PCSK9 antibodies have published cardiovascular outcomes trial data; inclisiran does not yet. If injection burden is a barrier to staying on treatment, inclisiran's schedule may help. If your doctor wants outcomes evidence before prescribing, the monoclonal antibodies have it. Either way, the decision belongs in a conversation with a lipid specialist who knows your full cardiovascular risk picture.